METHOD FOR ASSESSING THE RISK FOR INSULIN RESISTANT DIABETES AND/OR HEART DISEASE

摘要

Levels of the protein glycosylphosphatidylinositol specific phospholipase D (GPI-PLD) correlate with an increased risk of developing Type II diabetes and heart disease. Diagnostic tests and test kits are used to identify individuals at elevated risk for developing these conditions based on abnormal levels of GDIPLD in samples collected from patients. A method of identifying compounds that can lower the level of glycosylphosphatidylinositol specific phospholipase D (GPI-PLD in at risk patients is also disclosed. Compounds that alter the amount of GPI-PLD, such as the compound Wy 14, 643 are also disclosed. One of the methods for measuring GDI-PLD levels in various samples are antibody based methods using antibody raised in animals to the protein GDI-PLD. Still another method for measuring GDI-PLD levels involves measuring the activity of GDI-PLD in various samples thought to include GDI-PLD by following the conversion of at least one GDI-PLD substrate or an analogues of at least one GDI-PLD substrate.